These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 35313965)
1. Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention. Li YR; Dunn ZS; Garcia G; Carmona C; Zhou Y; Lee D; Yu J; Huang J; Kim JT; Arumugaswami V; Wang P; Yang L Stem Cell Res Ther; 2022 Mar; 13(1):112. PubMed ID: 35313965 [TBL] [Abstract][Full Text] [Related]
2. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Li YR; Zhou Y; Kim YJ; Zhu Y; Ma F; Yu J; Wang YC; Chen X; Li Z; Zeng S; Wang X; Lee D; Ku J; Tsao T; Hardoy C; Huang J; Cheng D; Montel-Hagen A; Seet CS; Crooks GM; Larson SM; Sasine JP; Wang X; Pellegrini M; Ribas A; Kohn DB; Witte O; Wang P; Yang L Cell Rep Med; 2021 Nov; 2(11):100449. PubMed ID: 34841295 [TBL] [Abstract][Full Text] [Related]
3. Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. Zhu Y; Smith DJ; Zhou Y; Li YR; Yu J; Lee D; Wang YC; Di Biase S; Wang X; Hardoy C; Ku J; Tsao T; Lin LJ; Pham AT; Moon H; McLaughlin J; Cheng D; Hollis RP; Campo-Fernandez B; Urbinati F; Wei L; Pang L; Rezek V; Berent-Maoz B; Macabali MH; Gjertson D; Wang X; Galic Z; Kitchen SG; An DS; Hu-Lieskovan S; Kaplan-Lefko PJ; De Oliveira SN; Seet CS; Larson SM; Forman SJ; Heath JR; Zack JA; Crooks GM; Radu CG; Ribas A; Kohn DB; Witte ON; Yang L Cell Stem Cell; 2019 Oct; 25(4):542-557.e9. PubMed ID: 31495780 [TBL] [Abstract][Full Text] [Related]
4. Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers. Li YR; Zeng S; Dunn ZS; Zhou Y; Li Z; Yu J; Wang YC; Ku J; Cook N; Kramer A; Yang L iScience; 2022 Sep; 25(9):104859. PubMed ID: 36034226 [TBL] [Abstract][Full Text] [Related]
5. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy. Li YR; Zhou Y; Yu J; Zhu Y; Lee D; Zhu E; Li Z; Kim YJ; Zhou K; Fang Y; Lyu Z; Chen Y; Tian Y; Huang J; Cen X; Husman T; Cho JM; Hsiai T; Zhou JJ; Wang P; Puliafito BR; Larson SM; Yang L Mol Ther; 2024 Jun; 32(6):1849-1874. PubMed ID: 38584391 [TBL] [Abstract][Full Text] [Related]
6. Genetic engineering of hematopoietic stem cells to generate invariant natural killer T cells. Smith DJ; Liu S; Ji S; Li B; McLaughlin J; Cheng D; Witte ON; Yang L Proc Natl Acad Sci U S A; 2015 Feb; 112(5):1523-8. PubMed ID: 25605948 [TBL] [Abstract][Full Text] [Related]
7. Methods for Studying Mouse and Human Invariant Natural Killer T Cells. Zhou Y; Li YR; Zeng S; Yang L Methods Mol Biol; 2021; 2388():35-57. PubMed ID: 34524660 [TBL] [Abstract][Full Text] [Related]
14. Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming. Simonetta F; Lohmeyer JK; Hirai T; Maas-Bauer K; Alvarez M; Wenokur AS; Baker J; Aalipour A; Ji X; Haile S; Mackall CL; Negrin RS Clin Cancer Res; 2021 Nov; 27(21):6054-6064. PubMed ID: 34376537 [TBL] [Abstract][Full Text] [Related]
15. Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients. Kimura M; Ferreira VH; Kothari S; Pasic I; Mattsson JI; Kulasingam V; Humar A; Mah A; Delisle JS; Ierullo M; Majchrzak-Kita B; Kumar D; Hosseini-Moghaddam SM Transplant Cell Ther; 2022 Oct; 28(10):706.e1-706.e10. PubMed ID: 35914727 [TBL] [Abstract][Full Text] [Related]
16. The role of unconventional T cells in COVID-19. Orumaa K; Dunne MR Ir J Med Sci; 2022 Apr; 191(2):519-528. PubMed ID: 34050887 [TBL] [Abstract][Full Text] [Related]
17. Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional. Sun W; Wang Y; East JE; Kimball AS; Tkaczuk K; Kesmodel S; Strome SE; Webb TJ Cytokine; 2015 Mar; 72(1):48-57. PubMed ID: 25569376 [TBL] [Abstract][Full Text] [Related]
18. Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia. Schmid H; Schneidawind C; Jahnke S; Kettemann F; Secker KA; Duerr-Stoerzer S; Keppeler H; Kanz L; Savage PB; Schneidawind D Front Immunol; 2018; 9():1817. PubMed ID: 30127790 [TBL] [Abstract][Full Text] [Related]
19. Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment. Kim N; Lee JM; Oh EJ; Jekarl DW; Lee DG; Im KI; Cho SG Front Immunol; 2021; 12():751869. PubMed ID: 35003063 [TBL] [Abstract][Full Text] [Related]
20. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study. Barkhordar M; Chahardouli B; Biglari A; Ahmadvand M; Bahri T; Alaeddini F; Sharifi Aliabadi L; Noorani SS; Bagheri Amiri F; Biglari M; Shemshadi MR; Ghavamzadeh A; Vaezi M Front Immunol; 2023; 14():1169666. PubMed ID: 37153556 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]